Mutations: NF1, TP53

Copy-number alterations: AKT2, ERBB2

Treatment phase: Primary

Treatment strategy: NACT

Time of sampling: Treatment naiive

Tissue site: Ascites

Paired organoid available (different treatment phase): Yes

Homologous recombination status: SBS3 NEG